Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK), a subsidiary of China-based Abbisko Cayman Limited (HKEX Stock Code: 2256.HK), announced on Monday that it has completed dosing of the first patient in the Phase one clinical trial in advanced solid tumours for ABSK061, which is claimed to have become the first highly selective FGFR2/3 inhibitor advanced into clinical stage globally.
The clinical trial is named ABSK061-101, NCT05244551 and is a First-in-Human Phase 1 study of the product to evaluate the safety, tolerability, pharmacokinetics in patients with advanced solid tumours, and to determine the Recommended Phase two Dose (RP2D) and assess preliminary anti-tumour activities. Presently, the trial is being carried out in both China and US.
The product is a new orally available, highly potent and selective small molecule FGFR2/3 inhibitor independently discovered and developed by Abbisko Therapeutics with global intellectual property rights.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients